Drugs / BiCAR-NK/T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03931720 | May 2019 → May 2021 | cancer | Asclepius Technology Company Group (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BiCAR-NK/T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03931720 ↗ |
| Known as | ROBO1 CAR-NK/T cells | “BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)” NCT03931720 ↗ |
| Modality | Cell therapy | “ROBO1 CAR-NK/T cell immunotherapy” NCT03931720 ↗ |